H.C. Wainwright raised the firm’s price target on Genmab (GMAB) to $36 from $35 and keeps a Buy rating on the shares following the Q2 report. The ...

Genmab has announced that its phase 3 EPCORE FL-1 trial met both primary endpoints in patients with relapsed or refractory ...

DelveInsight's,“ Fallopian Tube Cancer Pipeline Insight 2025 ” report provides comprehensive insights about 70+ Fallopian ...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

Genmab ( ($GMAB) ) has issued an update. On August 12, 2025, Genmab A/S announced a capital increase of 4,563 shares following the exercise of ...

Genmab A/S (NASDAQ:GMAB) is one of the top most undervalued biotech stocks to buy now. On August 7, William Blair analyst ...

Results from the Phase III EPCORE FL-1 trial (NCT05409066) showed that patients treated with Epkinly (epcoritamab) in ...